Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on May 15, 2017. The report details the entry into a material definitive agreement regarding an underwritten secondary public offering of the company's Class A common stock.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a secondary stock offering.
Material Changes and Events
- Secondary Offering: On May 15, 2017, the Company and its operating subsidiary entered into an underwriting agreement with Morgan Stanley & Co. LLC and other underwriters.
- Shares Sold: The offering involved the sale of 7,000,000 shares of Class A common stock by "Selling Stockholders," including affiliates of TPG Global, LLC, The Advisory Board Company, UPMC, Ptolemy Capital, LLC, and certain management stockholders.
- Proceeds: As this was a secondary offering, the proceeds were received by the Selling Stockholders, not the Company.
- Closing Date: The offering closed on May 19, 2017.
- Registration: The offering was made pursuant to a registration statement on Form S-3 (File No. 333-212709) declared effective on August 12, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It notes that the Underwriting Agreement includes customary representations, warranties, covenants, and indemnification provisions. The text does not disclose specific risks or contingencies beyond those inherent in the standard underwriting agreement referenced in Exhibit 1.1.
Investor Verification Checklist
- Verify the final sale price per share and total proceeds received by the Selling Stockholders in the full Prospectus Supplement dated May 15, 2017.
- Confirm the post-offering ownership percentages of the Selling Stockholders (TPG, UPMC, etc.) to assess potential dilution or control changes.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific lock-up agreements or indemnification liabilities.
- Check subsequent filings for any changes in the Company's capital structure resulting from this transaction.